JEF

Investing.com-- Jefferies updated its outlook on several U.S. software stocks, highlighting opportunities across observability platforms, enterprise technology and cloud-based tools going into the September quarter earnings season. Still guessing which stocks will beat the market? Our AI portfolio updates monthly and is outperforming the S&P 500 by 118%. See this month's list » The firm identified companies with strong execution and reasonable valuations, while flagging risks for others facing elevated expectations or competitive pressures. The analysis comes as software companies navigate varying demand environments and the evolving impact of artificial intelligence on their businesses. Dynatrace Jefferies maintained its "buy" rating and $75 price target on the observability platform provider. The firm said Dynatrace entered its fiscal second-quarter report with a cushion after a strong prior quarter, with Street expectations for new recurring revenue looking modest. Rising consumption should increasingly flow into recurring revenue as several large platform-subscription cohorts come up for renewal, mostly in the second half of the year. Jefferies called the company a reasonably valued way to play observability and enterprise adoption of AI agents, though it flagged sales execution and share loss to Datadog as risks. IBM Jefferies kept its "buy" rating and raised its price target to $270 from $260. The firm said IBM faced a show-me third quarter with a lowered bar, after a second-quarter miss it blamed on execution problems and slipped mainframe deals. It viewed the slippage as deferred rather than lost business and said customer checks showed mainframe workloads remained mission critical. The stock should grind higher if IBM recovered most of the delayed deals, showed software growth turning and raised or narrowed its full-year outlook, Jefferies said. Datadog Jefferies maintained its "hold" rating but cut its price target to $280 from $300. The firm said Datadog's fundamentals remained best in class, with revenue growth accelerating for six straight quarters and strength broadening well beyond AI-native customers. The setup into the third quarter was tougher, however, as expectations were elevated after a steep share rally and its largest customer was expected to start trimming usage. Valuation was Jefferies' main objection, and it saw better risk-reward in other AI infrastructure names such as Snowflake. Palantir Unsure what to buy ahead of earnings? Our AI's recent pre-earnings calls delivered gains of +77% to +118% after results dropped. See this month's earnings picks » Jefferies kept its "underperform" rating and $80 price target. The firm said Palantir delivered standout execution but faced a harder setup into the third quarter, with consensus revenue already above the top of company guidance and comparisons getting tougher in the second half. The stock's sharp run since the last report left little room for error, while competition from frontier AI labs and Databricks was intensifying. Jefferies credited the company's growth and profitability but called valuation full. Atlassian Jefferies maintained its "buy" rating and raised its price target to $245 from $200. The firm expected Atlassian to beat revenue estimates in its fiscal first quarter, helped by the easiest comparison of the year, larger enterprise deals and accelerating contracted backlog. The expected slowdown in total revenue growth next year was a mechanical effect of ending support for data-center products and the shift to the cloud, and it saw growth re-accelerating after that. Jefferies acknowledged the stock's big run raised the bar but said valuation sat at a discount to high-growth peers. Procore Jefferies kept its "buy" rating and $75 price target. The firm said Procore offered upside despite macro noise, after the stock sold off on worries about higher interest rates following a September rate hike. The company had executed well through the uncertainty and forward-looking macro indicators were mostly positive. Jefferies saw a path to modest re-acceleration on cross-selling, volume expansion and international growth, with room for margins to improve, and called the entry point attractive. Roper Jefferies maintained its "buy" rating and $500 price target. The firm said Roper's third-quarter bar looked achievable, but the stock remained a show-me story until growth inflected. Expectations were reasonable after solid first-half execution, and green shoots at Deltek and Neptune, its two largest businesses, were encouraging, though investors still wondered whether the company was fully out of the woods. Jefferies welcomed Roper's tilt toward acquisitions over buybacks but noted it had deployed little of its firepower and called valuation attractive. Monday.com Jefferies kept its "hold" rating and $95 price target. The firm said monday.com's third quarter looked beatable, helped by an easier comparison and what it viewed as prudent guidance. AI monetization was starting to show, with AI-related recurring revenue growing rapidly. But it flagged near-term disruption risk from July's workforce cut of about a fifth and a dip in net dollar retention as earlier price increases lapped. Longer-term AI risk loomed because workflow tools looked more exposed than heavy systems of record, Jefferies said. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C. Original Article Top Software Stocks to Watch Going Into Sept-Qtr Earnings, According to Jefferies Asia stocks slide as AI doubts deepen, Korean chips fall European stocks buckle as French yields cross 5% barrier

Investing.com -- Jefferies has updated its fashion sector rankings ahead of third-quarter earnings reports, highlighting Ralph Lauren as its top pick while adjusting expectations across several major apparel brands based on recent alternative data trends. Still guessing which stocks will beat the market? Our AI portfolio updates monthly and is outperforming the S&P 500 by 118%. See this month's list » The investment firm raised revenue and earnings estimates for some companies while trimming forecasts for others, reflecting mixed consumer demand signals heading into the critical holiday shopping season. The analysis focuses on key metrics including regional sales performance, margin expansion potential, and second-half year inflection points. Ralph Lauren (NYSE:RL) Unsure what to buy ahead of earnings? Our AI's recent pre-earnings calls delivered gains of +77% to +118% after results dropped. See this month's earnings picks » Jefferies maintains Ralph Lauren as its top pick with a Buy rating and $450 price target. The firm raised its fiscal second-quarter revenue estimate to 7.0% constant currency growth from 6.1%, above the Street's 6.4% consensus. Earnings per share estimates increased to $4.28 from $4.18, compared to the $4.23 Street consensus. The upgrade reflects stronger U.S. alternative data trends, with North America retail growth estimates raised to 5.5% from 4.0%. Asia retail growth estimates also increased to 18.0% from 14.4%. Jefferies expects the company to beat and raise guidance while maintaining prudent second-half assumptions. The firm sees continued upside opportunities in North America and Asia, along with further gross margin percentage improvements. Deckers (NYSE:DECK) Jefferies rates Deckers a Buy with a $120 price target, lowered from $130. The firm models fiscal second-quarter results slightly below consensus on revenue but above on earnings. Jefferies trimmed its HOKA direct-to-consumer estimates based on mixed alternative data and cautious peer commentary, while also slightly reducing UGG back-half projections. The firm notes that potential tariff refunds of $120 million could add approximately $0.68 to earnings per share this year, though management is expected to reinvest proceeds for growth. Accelerated share buybacks could drive meaningful earnings upside. The price target reduction reflects slightly lower near-term HOKA expectations, with the valuation based on 14 times price-to-earnings, down from 15 times previously. Original Article Jefferies names top fashion stocks ahead of earnings season Moderna shares plunge on cancer vaccine data leak Meta's new Class C stock to keep Zuckerberg in California, fund AI spending spree

Investing.com -- Jefferies analysts identified their preferred mid-cap biotechnology stocks ahead of third-quarter earnings, with Oncorus (ONC) emerging as their top commercial pick, followed by Revolution Medicines (RVMD) and Alnylam Pharmaceuticals (ALNY). The firm made several price target adjustments across its coverage universe while maintaining buy ratings on select names. Still guessing which stocks will beat the market? Our AI portfolio updates monthly and is outperforming the S&P 500 by 118%. See this month's list » The analysts noted they are closely monitoring earnings results for specific catalysts, including first revenue reports, potential earnings beats, and pipeline updates across their mid-cap biotech coverage. 1. Oncorus (ONC) Jefferies rates the stock Buy with a $410 price target, up from $405. The firm models third-quarter Brukinsa revenue at approximately $1.36 billion worldwide and $982 million in the United States, compared to consensus estimates of $1.30 billion and $929 million, respectively. Both IQVIA and Symphony data point to performance above consensus. Jefferies expects updates on the BTK CDAC accelerated approval pathway and GPC3 commercialization strategy. Management is currently in FDA discussions regarding the accelerated approval path for double-versus triple-exposed patients, with clarity expected by the third-quarter call. The firm noted management does not view Eli Lilly's Jaypirca first-line CLL approval as a competitive threat. Unsure what to buy ahead of earnings? Our AI's recent pre-earnings calls delivered gains of +77% to +118% after results dropped. See this month's earnings picks » 2. Revolution Medicines (RVMD) Jefferies models third-quarter Rasonque revenue at approximately $31.5 million versus consensus of $29.2 million. Symphony data shows 591 September total prescriptions and 645 cumulative prescriptions through October 2. The 150mg dosage represents approximately 78% of total prescriptions, which the firm views as an encouraging early indicator of real-world tolerability. Jefferies noted that investor expectations vary widely, with $50 million being the most frequently cited figure. The firm emphasized that focus should shift to fourth-quarter execution and fourth-quarter 2026 G12D CRC combination data, where investors are looking for 40-60% overall response rate with supportive durability. 3. Alnylam Pharmaceuticals (ALNY) Jefferies maintains a Hold rating but lowered its price target to $250 from $260. The firm models third-quarter Amvuttra revenue at approximately $1.17 billion worldwide and $950 million in the United States, compared to consensus of $1.12 billion and $883 million. Jefferies believes the 14th selling week nuance is not fully reflected in consensus estimates. The 340B program represents a key concern, with exposure likely exceeding 40%, though the impact will not be clear until 2027 quarters. Original Article Jefferies Highlights Top Mid-Cap Biotech Stocks Ahead of Earnings UBS bullish on Bouygues as cash flow cushions French fiscal risks Can AI avoid the boom-and-bust fate of past capital cycles? BofA weighs in

- Jefferies maintained its 'Buy' rating and $175 price target on Shopify, citing potential GMV growth. - The firm said strong earnings and the Muse AI shopping partnership could lift Shopify shares. - Shopify will report its third-quarter earnings on Nov. 3. Shopify Inc. (SHOP) is on track for a fourth straight week of gains, with analysts seeing up to 10% upside ahead of its fiscal third-quarter (Q3) 2026 earnings results. Jefferies expects stronger gross merchandise volume (GMV), while Baird raised its price target to $190, adding to optimism. Shopify stock traded over 1% lower overnight, ahead of Thursday. The stock has gained nearly 1% so far this week. See what 10M+ investors are talking about. Get the Stocktwits Daily Rip for what retail is watching right now, free to your inbox Jefferies reaffirmed its 'Buy' rating and $175 price target on Shopify. The firm said its review of third-party data indicated that GMV could exceed expectations, offering a positive signal ahead of the company's quarterly results. The firm also sees a reasonable outlook for Q4. While Shopify shares have already gained on earnings expectations, Jefferies believes strong performance and clearer details on the company's relationship with Muse could provide fresh support for the stock. Meta Platforms (META) and Shopify are partnering to let Meta's personal AI assistant, Muse, buy products from stores on Shopify's platform for users. Shopify said the feature will work with Shop Pay, its one-tap checkout service that saves customers' payment and shipping details. In an X post last month, Shopify CEO Tobi Lutke said, "We are excited to announce we are partnering deeply with Muse to enable agentic checkout with Shop Pay on all Shopify stores, offering people an easy and delightful way to shop and check out with Muse." Baird raised its price target on Shopify to $190 from $160 and maintained an 'Outperform' rating. The revised price target implied a 10% upside from its last closing price. Similarly, on Monday, Cantor Fitzgerald raised its price target on SHOP to $158 from $145 but kept a 'Neutral' rating. The firm expects Shopify to beat Q3 estimates for GMV, revenue and operating profit, with sales growth in the low 30% range. Shopify is scheduled to report its Q3 earnings on Nov. 3. According to Fiscal.ai data, analysts see $3.74 billion in revenue and earnings of $0.46 per share. GMV trends and outlook could help determine whether the stock has room to run further. On Stocktwits, retail sentiment around the stock remained in 'neutral' territory. A user said, "Earnings is here in under 3 weeks! Today everything is red, by Friday this is over $180!." Another user said, "The institutions that bought this up in the last 2 weeks are going to lose a lot of money soon." SHOP stock has gained 7% year-to-date. Also see: FUN Stock Heads For Worst Week Since COVID-19 Pandemic: Rider Death, Financial Woes Pile Up Ahead Of Earnings For updates and corrections, email newsroom[at]stocktwits[dot]com. Shivani Kumaresan has no position in any of the stocks mentioned in this article. StockTwits' news team content is for informational purposes only and is not intended as investment advice. For more, see our editorial policy. This article was originally published on StockTwits. Related: - SOXX Extends Selloff After 8-Day Decline, KOSPI Rebounds: Jim Cramer Calls SK Hynix 'Epicenter Of Fear' - COST Stock Heads For Best Week Since May: Costco's Digital Sales And Membership Growth Get Bullish Call From Analyst - HIMS Stock Snaps 3-Day Slump On Peptide Hopes: Trump Administration Reviews Plan That Could Unlock $2.2B Market

Jefferies survey points to faster market growth in 2027, with cloud security and broader platforms emerging as priorities. Cybersecurity sales pipelines strengthened in the third quarter, with no surveyed reseller reporting a decline for the first time in 11 quarters, Jefferies found. The investment bank's survey of 25 value-added resellers estimated average pipeline growth at 5.6%, up from 3.9% in the second quarter. 76% of respondents reported improving pipelines over the previous three months, 24% saw no change, and 0% reported a decline. Resellers raised their expected cybersecurity market growth for the calendar year 2026 to 10.2%, from 9.6% in July, and forecast growth accelerating to 12.2% in 2027. The findings point to strengthening demand as customers increasingly consolidate security spending around fewer suppliers and integrated technology platforms. Survey respondents described buyers moving away from stand-alone security tools towards integrated suites covering network security, cloud protection, identity and data governance. Jefferies identified Cloudflare, the internet infrastructure and security company, Palo Alto Networks Inc (NYSE:PANW, XETRA:5AP), the cybersecurity platform provider, and CrowdStrike Holdings Inc (NASDAQ:CRWD), the endpoint security specialist, as leading performers in reseller feedback. The three companies recorded net performance scores of 58%, 56% and 43%, respectively, measuring the proportion of respondents reporting results above plan minus those reporting results below plan. Cloud security emerged as the fastest-growing expected category over the next 12 months and the leading area for investment aimed at securing generative artificial intelligence (AI) systems. AI-related security spending is also beginning to feed through, with 88% of respondents reporting that customer budgets had changed or were expected to change following security concerns associated with Mythos. 44% said the spending benefit began in the third quarter, while another 24% expected it to emerge during the final three months of 2026. Microsoft strengthened its perceived lead in agentic identity security, with 60% of respondents identifying it as well positioned, while CyberArk/Palo Alto Networks and CrowdStrike each received 48%. Higher memory prices may also be accelerating purchases of firewall appliances, with an average of 48% of respondents reporting some pull-forward in spending across Palo Alto Networks, Fortinet and Check Point. The report cautioned that the findings reflect a limited sample of 25 resellers surveyed in early October and do not quantify the financial impact of AI-related budget increases.

Jefferies maintained a 'buy' rating on AstraZeneca PLC (LSE:AZN, NASDAQ:AZN), the biopharmaceutical company, with a 17,500p price target, representing 46% potential upside from its 11,958p share price. The broker expects AstraZeneca to report third-quarter revenue about 1% ahead of the Visible Alpha consensus and core earnings before interest and tax at 3% above expectations. Jefferies anticipates that higher alliance revenue and royalties, along with modestly lower operating expenses, will support the outperformance. The broker expects AstraZeneca to reiterate its 2026 guidance despite the expected third-quarter outperformance while seeing potential upside to consensus estimates for the year. Jefferies noted that the expected beat comes despite faster erosion in US Farxiga sales and what it describes as softer Lynparza volumes. The broker remains positive on AVANZAR, AstraZeneca's lung cancer trial, and believes the study is reasonably likely to show a progression-free survival benefit in the QCS biomarker-positive population. Progression-free survival measures how long patients live before their disease worsens, and Jefferies considers a failure on both progression-free survival endpoints to be a low-probability outcome. Jefferies also sees a potential catalyst from Summit Therapeutics' HARMONi-3 trial, saying a positive result could increase the strategic importance of ivonescimab to AstraZeneca. The broker highlighted AstraZeneca's strategy of combining PD-1 and vascular endothelial growth factor biology with its expanding antibody-drug conjugate portfolio across major cancer types. Jefferies noted that AstraZeneca's $2 billion equity investment in Summit limits the financial downside from potential trial failure. The broker also believes AstraZeneca can continue growing beyond 2030, despite its $80 billion revenue target for that year being largely de-risked through existing franchises and indication expansion. Jefferies estimates that AstraZeneca needs to de-risk about $10 billion of incremental revenue by 2034 to sustain annual revenue growth of about 3% after 2030. The broker said the potential 2027 catalyst set provides enough opportunities to achieve that target and reiterated its Buy rating. Its price target values AstraZeneca at about a 50% premium to the European pharmaceutical sector on 2027 forecast earnings, although Jefferies expects its price-to-earnings growth ratio to remain broadly in line with the sector.

Jefferies Financial Group has delivered a 43.3% gain over the past 5 years. However, the recent share price pullback and shifting mix of fee income raise a sharper question about whether the returns it earns on its capital are enough to support where the stock trades today. - That 43.3% return over 5 years puts real weight on the issue of whether Jefferies is generating strong enough returns on the capital it deploys to justify the journey so far. - Recent news pointing to stronger investment banking and equity underwriting activity, alongside softer fixed income trading, can influence how efficiently the group turns its capital base into future earnings power. - If you'd rather focus on earnings, this one's for you. See why Jefferies Financial Group's 12.6x P/E tells a different valuation story. The stock's next move may depend on whether the returns Jefferies earns on its capital are strong enough to make the current valuation look sensible. If you want a broader watchlist of capital return stories alongside Jefferies Financial Group, a focused stock screen built around 31 high quality undervalued stocks. The Excess Returns model for Jefferies Financial Group looks at whether the profit it earns on shareholder capital clears the hurdle set by its funding cost. Jefferies carries a Book Value of $51.95 per share and a Stable EPS estimate of $4.76 per share, while the Average Return on Equity of 8.57% is set against a Cost of Equity of $6.97 per share. That spread matters because the model currently points to an Excess Return of $2.21 per share falling short of the required return, even with a Stable Book Value projection of $55.57 per share. With Jefferies trading around $45.73, the Excess Returns framework indicates the estimated intrinsic value is substantially below the current share price. Jefferies' recent Q3 2026 earnings beat, driven by strong investment banking and equity underwriting revenue, helps explain why the market is pricing the shares where they are despite what the model implies about returns on capital. Find out what Jefferies Financial Group could be worth using our Excess Returns estimate. Jefferies Financial Group's recent valuation puzzle raises a natural next question for you as a shareholder or watcher. Narratives on Simply Wall St's Community page spell out the future earnings, growth and margin paths that would need to hold for the stock to be worth materially more or less than where it trades now. Where a single ratio or model gives one neat number, these storylines unpack the specific future it relies on so you can check whether reality is tracking it. A written, number driven Narrative on Jefferies Financial Group gives you a clear view on whether the recent earnings beat, stronger investment banking fees and weaker fixed income trading can support the returns the business earns on its capital. It turns those views into specific assumptions on growth, margins and capital efficiency that can be checked against each new result as it lands. Share your own Narrative for Jefferies Financial Group and set out the assumptions behind your valuation. Numbers only tell part of the story for Jefferies Financial Group, because the people directing capital and the way their pay is structured can heavily shape how that story plays out. See who runs Jefferies Financial Group and how they are paid. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include JEF. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

Investing.com - Jefferies is calling the peak of the global semiconductor upcycle for Q4 2026, warning that multiple compression is already eating into European chip stocks even as underlying demand holds firm. Before you buy NVIDIA: our AI model's stock picks are beating the market by 120%+. See the list now » Jefferies analyst Janardan Menon, writing in a Q3 2026 semiconductor and tech hardware earnings preview, argues the cycle peak is being driven primarily by an adverse base effect from the sharp spike in DRAM prices in Q4 2025. "Semiconductor demand remains strong and most companies are expected to at least meet CYQ3 expectations," Menon wrote. "However, earnings upgrades may be limited, which could result in stocks fading." The most direct equity expression of this multiple-compression thesis is Infineon Technologies, which Jefferies simultaneously names as a top pick — an apparent contradiction that reflects the firm's view that select names with underappreciated 2027 earnings can outrun the sector de-rating. The timing of the valuation pressure is a central concern in the note. Jefferies points out that sector valuation multiples historically pre-empt cycle peaks and troughs by around 3-6 months, and argues that trend has already been visible since July 2025. "While short periods of re-rating are possible, historical trends suggest that multiples are directionally likely to head lower in the medium term," Menon said. That backdrop leads the firm to a cautious overall sector view: "This could continue to deliver somewhat lacklustre medium term performance from most European semiconductor stocks in our view, despite ongoing strength in chip demand." Not finding the right stocks? Our AI's list of investor-grade stock picks for October just dropped » Heading into the Q3 2026 reporting season, Jefferies expects most semiconductor companies to at least meet consensus forecasts on revenues and margins. The catch: with the cycle maturing and only one quarter left in 2026, the firm anticipates that beats and raises will be modest, "limiting upgrades to earnings estimates," according to the report. That limits the fuel available for any sustained re-rating. Against that cautious backdrop, Jefferies narrows its conviction to three names. "We prefer stocks where we believe market expectations for 2027 are too conservative, or where new demand or margin drivers could emerge over the next year or so," Menon said. Nokia, ams OSRAM, and Infineon are the firm's top picks, each selected on the basis that FY2027 earnings could outperform what consensus currently prices in. Jefferies is explicit that 2027 consensus estimates for Nokia are too low, per the report. On Infineon, the firm sees the company benefiting through 2027 from rising prices and a possible acceleration in the automotive cycle. For the semiconductor capital equipment segment, the picture is constructive on demand but stretched on valuation. Jefferies expects ASML to stay with its plan to build 85 EUV systems in 2027 and 110 in 2028, with some additional capacity available if needed. ASM International is seen continuing to recover in DRAM revenues after a soft first half of 2026, with the A14 node cited as a key part of its 2027 growth story. But Jefferies warns that bullish semicap forecasts for 2027 already leave limited scope for upside, and flags the MATCH Act as an ongoing legislative concern for the segment. The most significant tail risk the firm identifies cuts across the entire semiconductor supply chain. "Any deceleration in AI investment growth would have a material negative impact on the semiconductor supply chain due to inventory build," Menon wrote. Growing concerns around power availability, pushbacks to data centre construction, and pacing of AI capital spending are, in Jefferies' view, already adding to valuation pressure on the sector. Original Article 3 European chip stocks to buy for Q3 earnings season: Jefferies HPE shares surge on upgraded networking outlook and $1.2B Vultr AI deal Apple to unveil smart-home hub on Oct. 13 in major AI push - Bloomberg

Investing.com -- Jefferies downgraded Italian insurer Generali to "hold" from "buy" on Wednesday, saying its new €38 price target no longer offered sufficient total shareholder return to justify a buy rating after a sharp rise in the shares. Still guessing which names to buy? Our AI rebuilds its stock picks at the start of every month. The list is beating the market by 120%. See what's on it » Generali closed at €43.07 on Tuesday, putting Jefferies' new target 12% below the latest closing price. The broker raised its target from €28.50 after rolling its valuation forward to 2027 normalised earnings from 2025. Jefferies said Generali shares had risen 123% since Giulio Terzariol joined the group in January 2024, compared with a 52% gain for the SXIP insurance index. The one-year forward price-to-earnings multiple had also expanded to more than 12 times from less than eight times over the same period, they said. The analysts retained a constructive view of Generali's strategy but said the stock now reflected much of the improvement. The shares recently hit a record high and have traded between €31.76 and €46.24 over the past year. Should you buy NVIDIA right now? Before you decide, consider this: an AI-powered list of stock picks is outperforming the market by 120%, and it updates at the start of every month. See this month's picks » Jefferies raised its earnings forecasts, increasing its 2026 earnings-per-share estimate by 7% to €3.30 and its 2027 estimate by 5%. Its 2026 forecast is 2% above consensus, according to Visible Alpha. Ahead of Generali's nine-month results, due on Nov. 13, Jefferies flagged several potential constraints on further earnings upgrades. In non-life insurance, the broker expects retail pricing trends to deteriorate, limiting scope for further improvement in market expectations despite Generali's strong underwriting performance. It also said local weather conditions had become less favourable, although there had been few globally significant catastrophe events. In life insurance, investor optimism over potential benefits from German pension reform has given way to concerns over lapse rates in Generali's existing book and margins in the highly competitive new business market, Jefferies said. Generali and Allianz both trade at more than 13 times expected 2026 earnings, according to Jefferies, while AXA trades at around 11 times. Jefferies rates AXA "buy" and Allianz "hold". Jefferies' €38 base-case valuation assumes recurring annual share buybacks of €500 million and a non-life combined ratio of 92.4%. Its €50 upside case assumes €1 billion of recurring buybacks and an 87.5% combined ratio, while its €30 downside case assumes no further buybacks and a 95.5% combined ratio. Generali has a market capitalisation of about €66.1 billion. The insurer is due to hold its 2026 Investor Day on Nov. 18. Looking for the next multi-bagger? This AI enabler is up 90%+ since picked by our AI models in July -- and still has a 62% upside » Original Article Jefferies sees limited Generali upside after strong earnings-driven rally Morgan Stanley upgrades Julius Baer after FINMA ends AML enforcement action Commerzbank shares fall as Deutsche Bank sees strategy uncertainty capping gains

- Jefferies expects Nike to post better-than-expected Q1 results, forecasting $11.5 billion in revenue and $0.48 EPS. - Jefferies sees over 100% upside in Nike stock. - Nike's stock has fallen more than 77% from its 2021 peak and has struggled with weaker lifestyle demand. Nike Inc. (NKE) is heading for a second straight monthly decline, but Jefferies sees a potential turnaround ahead. Analyst Randal Konik expects fiscal first-quarter (Q1) 2027 revenue and earnings to top Wall Street estimates, while November's investor day could provide another catalyst as Nike works to rebuild momentum. Nike stock inched 0.1% lower in Tuesday's premarket. The stock is headed for a second straight month of losses, after a more than 5% decline in September. See what 10M+ investors are talking about. Get the Stocktwits Daily Rip for what retail is watching right now, free to your inbox According to Jefferies, Nike could deliver a stronger-than-expected start to its fiscal year as investors look for signs that the athleticwear giant's turnaround is gaining traction. Analyst Konik expects Nike to generate $11.5 billion in Q1 revenue and $0.48 per share in earnings. Those estimates sit above Wall Street expectations of $11.3 billion in sales and $0.44 in earnings per share, according to Fiscal.ai data. Nike will report Q1 earnings on Oct. 1. The firm believes the company's progress could help lift confidence in its recovery after a period of weaker performance. Jefferies also pointed to Nike's investor day scheduled for November as an important event for shareholders. The analyst expects the company's longer-term outlook and guidance framework to provide a near-term catalyst for the stock. Jefferies maintained its Buy rating on Nike and kept its $75 price target unchanged, implying a 106% upside to the stock's last closing price. Nike is going through a difficult period, with its stock down more than 77% from its November 2021 peak. The drop has wiped out over $224 billion in market value and brought the stock's valuation to levels not seen since 2014. Nike's stock performed strongly after 2016, helped by high demand for casual sportswear during the pandemic, growing online sales and a strong market. But that momentum has since weakened. The company has faced years of challenges, including problems with its direct-to-consumer strategy, weaker relationships with retail partners, softer demand for lifestyle products and a long slowdown in China. Nike has also lost its place in the S&P 100 since Sept. 21 However, on Stocktwits, retail sentiment around the stock improved to 'bullish' from 'neutral' territory the previous day. A user said, "Earnings are coming up, and I'm expecting them to do something, anything, after being kicked out of the $SPY. Let's tune in and see." NKE stock has crashed 42% year-to-date. Also see: This Quantum Computing Stock Has Gained For Six Straight Sessions, With A Buy Call From BofA For updates and corrections, email newsroom[at]stocktwits[dot]com. Shivani Kumaresan has no position in any of the stocks mentioned in this article. StockTwits' news team content is for informational purposes only and is not intended as investment advice. For more, see our editorial policy. This article was originally published on StockTwits. Related: - NetApp Expands Cloud Reach With Native Oracle OCI Storage — Full Roll-Out Planned Within 12 Months - NetApp Expands Cloud Reach With Native Oracle OCI Storage — Full Roll-Out Planned Within 12 Months - SpaceX Could Deliver A Q3 Beat, Says UBS — Here's What's Expected To Drive Growth